Akeso, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Yu Xia
- Full Time Employees
- 3,761
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 6, Shennong Road Zhongshan GD China 528437
- IPO Date
- Apr 24, 2020
- Website
- akesobio.com
- Similar Companies
- Business
- Akeso, Inc. is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative antibody drugs globally. The company’s core product portfolio includes first-in-class and best-in-class immuno-oncology bispecific antibodies such as cadonilimab and ivonescimab, both approved and commercially marketed. Akeso focuses on immuno-oncology therapies targeting various cancers including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, colorectal cancer, and pancreatic cancer. The company also develops antibody-drug conjugates (ADCs) including novel bispecific ADCs like AK146D1 and HER-3 targeting ADC AK138D1, which are under global clinical trials. Beyond oncology, Akeso advances autoimmune and chronic disease treatments with products such as ebdarokimab (IL-12/IL-23), ebronucimab (PCSK9), gumokimab (IL-17), manfidokimab (IL-4Rα), and emerging candidates for neurological diseases. Founded in 2012 and headquartered in China, Akeso operates a fully integrated end-to-end drug development system, combining proprietary platforms like the ACE Platform and Tetrabody bispecific antibody technology with GMP-compliant manufacturing and global commercialization capabilities. The company targets both Chinese and international markets and is expanding its global clinical development and commercialization footprint. In the last 1-2 years, Akeso has accelerated its "IO 2.0 + ADC 2.0" strategy, advancing immuno-oncology bispecific antibodies and ADCs with multiple candidates progressing to global Phase III clinical trials. Significant milestones include U.S. FDA approval of penpulimab, market approvals for ebdarokimab, and expanded indications for cadonilimab and ivonescimab, which have been included in China's National Reimbursement Drug List, boosting commercial sales. Akeso has reported record commercial sales, driven by these lead products, and is preparing further Phase III trials for additional oncology and non-oncology indications. It has also established global partnerships and alliances to enhance clinical advancement and commercialization efforts, positioning itself as a global leader in bispecific antibody and ADC innovation. Akeso’s pipeline comprises over 50 innovative candidates with 24 in clinical trials, including 15 bispecific/multispecific antibodies and bispecific ADCs, covering cancer, autoimmune, inflammation, metabolic, and neurological diseases. This robust pipeline combined with recent strategic expansions and regulatory approvals forms the basis of Akeso’s growth into a fully integrated global biopharmaceutical entity.
Company News
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer
Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia